Autres langues Biofrontera Inc.

Actions

BFRI

US09077D2099

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,59 ^USD	-5,92 %		-5,92 %	-42,60 %

18/03	Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024
15/03	Biofrontera Inc. annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03
Biofrontera Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	11/03
Medicus Pharma Names COO	05/03
Biofrontera Inc. announced that it has received $8 million in funding	22/02
BIOFRONTERA AG ANNOUNCES REVISED STRATEGY	21/02
BIOFRONTERA AG, BIOFRONTERA TRANSFERS CLINICAL RESEARCH TO THE U.S.	21/02
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera Ag	20/02
Biofrontera Inc. announced that it expects to receive $8 million in funding	19/02
MORNING BRIEFING - Deutschland/Europa -2-	16/02
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use	05/02
Certain Warrants of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Common Stock of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Stock options of Biofrontera Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	11/01
Biofrontera Inc. Terminates MidCap Business Credit Loan Agreement	09/01
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023	09/11
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	09/11
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	10/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biofrontera Inc.

Actions

BFRI

US09077D2099

Autres langues

Filtres